-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor June 14, 2021, Debiopharm announced its CD37 targeting antibody conjugate (ADC) naratuximab emtansine, combined with rituximab (anti-CD20 antibody), in the treatment of relapsed/refractory Positive results were obtained in the Phase 2 clinical trial of R/R diffuse large B-cell lymphoma (DLBCL)
.
The trial results showed that the combination therapy achieved a complete response rate (CRR) of 31.
6% in R/R DLBCL patients who had received more than two previous treatments
.
The latest results presented at the European Hematology Association (EHA) annual meeting on June 12 showed that among refractory patients who have previously received more than two treatments, naratuximab emtansine combined with rituximab can be evaluated The objective response rate (ORR) in the patients (N=76) was 44.
7%, and the CRR was 31.
6%
.
The median duration of response (DoR) has not yet been reached.
66% of responders have a DoR greater than 12 months, showing the durability of the effect
.
In terms of safety, the safety characteristics of the combination therapy are predictable and manageable, the rate of treatment discontinuation due to adverse events is low (8%), and the incidence of severe febrile neutropenia is low (4%)
.
Naratuximab emtansine is a potentially innovative method for the treatment of patients with B-cell malignancies
.
This ADC binds to CD37 with high affinity and specificity, and the carried load DM1 can hinder the cell proliferation pathway after being released in the cell, and then induce cell cycle arrest and apoptosis
.
In addition to DLBCL, it also shows good potential in the treatment of mantle cell lymphoma, follicular lymphoma, and acute myeloid leukemia
.
Image source: Bioconjugator, CC BY-SA 4.
0 <https://creativecommons.
org/licenses/by-sa/4.
0>, via Wikimedia Commons In most countries around the world, NHL is listed as the 5th to 9th most common cancer In 2018, it is estimated that there will be more than 500,000 new cases
.
Although advances in NHL therapy have significantly improved the prognosis of patients, some patients still develop resistance to first-line and second-line therapies, or do not meet the requirements of stem cell transplantation therapy, which affects the survival of patients
.
The need to improve the prognosis of patients has led to the exploration of innovative treatment strategies, such as targeting the CD37 antigen on the basis of standard treatment methods
.
Diffuse large B-cell lymphoma is the most common aggressive NHL, accounting for 30-40% of all cases
.
Nearly half of the patients cannot be cured by first-line treatment, leaving a large number of patients at risk of worsening their condition
.
"We now see that this combination of targeting both CD37 and CD20 can address the unmet needs of DLBCL patients who have relapsed or did not respond to early treatment
.
" said Dr.
Bertrand Ducrey, CEO of Debiopharm, "These promising results And good safety features will encourage us to further explore the potential benefits that this powerful ADC technology may bring to patients
.
"Reference: [1] Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies.
Retrieved June 14, 2021, from https:// -antibody-drug-conjugate-shows-promising-phase-ii-results-for-the-treatment-of-b-cell-malignancies-301311534.
html Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.